PDF(1487 KB)
PDF(1487 KB)
PDF(1487 KB)
武汉市新型冠状病毒感染患儿用药情况的回顾性分析
A retrospective analysis of medication in children with SARS-CoV-2 infection in Wuhan, China
目的 分析武汉市新型冠状病毒（SARS-CoV-2）感染患儿的用药情况，为临床合理用药提供参考。方法 回顾性分析2020年1月26日至2020年3月5日确诊SARS-CoV-2感染患儿的临床资料，将患儿分为无症状组（n=41）和有症状组（n=73），在亚组分析中分别比较不同抗病毒治疗方案（单用、两联和三联）及干扰素α-1b是否联用阿奇霉素对患儿住院天数、SARS-CoV-2核酸转阴时间的影响。结果 共纳入114例确诊患儿，其中男72例（63.2%），女42例（36.8%）。患儿中位年龄为7.1岁，住院天数、SARS-CoV-2核酸转阴时间的中位数分别为10 d、6 d。亚组分析中，无论在有症状组或无症状组，患儿住院天数和SARS-CoV-2核酸转阴时间在不同抗病毒药物治疗方案及是否使用干扰素α-1b联用阿奇霉素治疗中比较差异均无统计学意义（P > 0.05）。结论 不推荐常规联用抗病毒药物治疗儿童SARS-CoV-2感染及以协同抗病毒为目的联用阿奇霉素。
Objective To study the medication in children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Wuhan, China, and to provide a reference for rational drug use in clinical practice. Methods A retrospective analysis was performed on the medical data of the children who were diagnosed with SARS-CoV-2 infection from January 26 to March 5, 2020. The children were divided into an asymptomatic group with 41 children and a symptomatic group with 73 children. A subgroup analysis was performed to investigate the effect of different antiviral regimens (monotherapy, double therapy, or triple therapy) and whether interferon α-1b was used in combination with azithromycin on the length of hospital stay and the clearance time of SARS-CoV-2 nucleic acid. Results A total of 114 children with SARS-CoV-2 infection (72 boys and 42 girls) were enrolled. The median age of the children was 7.1 years. The median length of hospital stay was 10 days and the clearance time of SARS-CoV-2 nucleic acid was 6 days. In either group, the subgroup analysis showed no significance differences in the length of hospital stay and the clearance time of SARS-CoV-2 nucleic acid between the subgroups treated with different combinations of antiviral drugs and the subgroups treated with interferon α-1b alone or in combination with azithromycin (P > 0.05). Conclusions It is not recommended to use the routine combinations of antiviral drugs for children with SARS-COV-2 infection or combine with azithromycin for the purpose of antiviral therapy.
新型冠状病毒 / 抗病毒药物 / 阿奇霉素 / 合理用药 / 儿童
Severe acute respiratory syndrome coronavirus 2 / Antiviral drug / Azithromycin / Rational drug use / Child
[1] Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern[J]. Lancet, 2020, 395(10223):470-473.
[2] Wu Z, Mcgoogan JM. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19) outbreak in China:summary of a report of 72314 cases from the Chinese center for disease control and prevention[J]. JAMA, 2020, 323(13):1239-1242.
[3] Grein J, Ohmagari N, Shin D, et al. Compassionate use of Remdesivir for patients with severe COVID-19[J]. N Engl J Med, 2020, 382(24):2327-2336.
[4] Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19:results of an openlabel non-randomized clinical trial[J]. Int J Antimicrob Agents, 2020, 56(1):105949.
[5] Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection[J]. Med Mal Infect, 2020, 50(4):384.
[6] 国家卫生健康委员会, 国家中医药管理局. 新型冠状病毒肺炎诊疗方案(试行第八版)[J]. 传染病信息, 2020, 33(4):289-296.
[7] Pan L, Mu M, Yang P, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China:a descriptive, cross-sectional, multicenter study[J]. Am J Gastroenterol, 2020, 115(5):766-773.
[8] Sutton D, Fuchs K, D'alton M, et al. Universal screening for SARS-CoV-2 in women admitted for delivery[J]. N Engl J Med, 2020, 382(22):2163-2164.
[9] 姜毅, 陆小霞, 金润铭, 等. 儿童新型冠状病毒感染诊断、治疗和预防专家共识(第二版)[J]. 中华实用儿科临床杂志, 2020, 35(2):143-150.
[10] 陈志敏, 傅君芬, 舒强, 等. 儿童2019冠状病毒病(COVID-19)诊疗指南(第二版)[J]. 浙江大学学报(医学版), 2020, 49(2):139-146.
[11] Drinevskiǐ VP, Osidak LV, Natsina VK, et al. Chemotherapeutics for treatment of influenza and other viral respiratory tract infections in children[J]. Antibiot Khimioter, 1998, 43(9):29-34.
[12] Loosli CG, Stinson SF, Ryan DP, et al. The destruction of type 2 pneumocytes by airborne influenza PR8-A virus; its effect on surfactant and lecithin content of the pneumonic lesions of mice[J]. Chest, 1975, 67(2 Suppl):7S-14S.
[13] Robinson KM, Kolls JK, Alcorn JF. The immunology of influenza virus-associated bacterial pneumonia[J]. Curr Opin Immunol, 2015, 34:59-67.
[14] Madrid PB, Panchal RG, Warren TK, et al. Evaluation of Ebola virus inhibitors for drug repurposing[J]. ACS Infect Dis, 2015, 1(7):317-326.
[15] Retallack H, Di Lullo E, Arias C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin[J]. Proc Natl Acad Sci U S A, 2016, 113(50):14408-14413.
